SGS Announces New Research Tax Credit Recognition
SGS Life Science Services is to bring added-value to French clients’ drug development activities, as SGS’ biologics testing laboratory in Wokingham (London) has been granted the French Research Tax Credit recognition (CIR – Crédit Impôt Recherche agrément) from the French Ministry for Higher Education and Research and the renewal of this recognition for its two French labs, based in Poitiers and in Clichy. As outlined in the French authorities’ guidelines, the French Research Tax Credit serves as a tax incentive for innovative companies involved in R&D activities, through which R&D-related expenditures may qualify for a tax credit.
“We are pleased that our French clients can now benefit from the “CIR” in a common R&D effort to increase the quality, safety and efficacy of their biologic drugs,” said Dr Chris Harbach, Manager, Chemical Services, SGS M-Scan, Wokingham, UK. “This official recognition and incentive will definitely strengthen the relationship with our French clients to perform preformulation and stability studies, post-translational modifications, protein characterization and biophysical analysis.”
The SGS Wokingham laboratory has received CIR recognition for 3 years, effective from 2014 until December 2016. For a company to include its R&D costs in their CIR, it must ensure that such costs qualify as R&D expenditures under the terms of the CIR, and that the subcontractor is recognized by the Health Ministry of France. The SGS Wokingham facility fulfils these criteria, as do its affiliate sites in France and Belgium (Wavre), which all received a renewal for the same period.
“Our clients based in France will now have a large and complementary scope of analytical services covered by this R&D Tax Credit, including bioanalytical, immuno assays, biologics formulation, protein characterisation and stability analysis and chemistry/microbiological quality control testing,” commented Paul Beyou, SGS Life Science Services’ Laboratory Manager in Clichy, France.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.